Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00435864 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorStudy Identification, Study Status, Referencesv7
NotablePrimary and study completion dates changed from estimate of Jul 2012 to Nov 2013Trial status: Recruiting to Completed · Enrollment target: estimated 60 to confirmed 92 · Site details revisedv6Show 3 more changesShow less
Trial status: Recruiting to Completed
Enrollment target: estimated 60 to confirmed 92
Site details revised
NotablePrimary and study completion dates: Jul 2011 to Jul 2012v5
NotableEnrollment target: 40 to 60Primary and study completion dates: Jul 2011 · Start date: Apr 2010 to Apr 2007 · Study arms: 0 to 3v4Show 3 more changesShow less
Primary and study completion dates: Jul 2011
Start date: Apr 2010 to Apr 2007
Study arms: 0 to 3
NotableStart date: Apr 2007 to Apr 2010v3
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 1 · Start date: Apr 2007 · Study title shortened, about 14 wordsv2Show 3 more changesShow less
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Numerous studies about the potential role of NK alloreactive during a n hematopoietic stem cells graft are based on genotypical analyses of the KIR receptors and on genotypic incompatibilities between KIR and HLA for couple donor/recipient. There is still a lot of issues non resolved: Are KIR really expressed and how occur their expression during time when hematopoietic reconstitution? Is it depending on HLA of the recipient?If KIR are expressed, what are the mechanisms of alloreactivity of NK cells? Are NK able to lyse tumoral cells? Could alloreactive NK cells constitute a therapeutic tool able to induce tolerance and elimination of leukemia during hematopoietic stem cells grafts?